A Phase 2 interventional study of Tolvaptan MR and Tolvaptan IR in Autosomal Dominant Polycystic Kidney Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2018-09-27.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.
Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 5th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 2, and was the 9th registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →
Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2011.
This study's enrollment of 178 is above the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 91 across the 18 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 18 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
17 studies in Polycystic Kidney, Autosomal Dominant by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 16 finished, 13 (81%) have results posted.
Among the 17 studies in Polycystic Kidney, Autosomal Dominant by Otsuka Holdings Co., Ltd., this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2011, is one of 5 in phase 2, and was the 10th registered.
Otsuka Holdings Co., Ltd.’s Polycystic Kidney, Autosomal Dominant studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 17 in Polycystic Kidney, Autosomal Dominant:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the short-term effects of two tolvaptan formulations in patients with ADPKD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with:
diagnosis of ADPKD by modified Ravine criteria:
Exclusion Criteria:
Subjects with:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tolvaptan MR 50 mg capsule and 2 placebo IR tablets ( 8 AM) and 1 placebo IR tablet (4 PM) daily.
Drug: Tolvaptan MR · Drug: Placebo
Tolvaptan MR 80 mg capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
Drug: Tolvaptan MR · Drug: Placebo
Two tolvaptan IR 30-mg tablets and 1 placebo MR capsule (8 AM) and 1 tolvaptan IR 30-mg tablet (4 PM) daily.
Drug: Tolvaptan IR · Drug: Placebo
Placebo MR capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
Drug: Placebo
50/80 mg capsules
Also known as: OPC-41061
60/30 mg capsules
Also known as: OPC-41061
tablet
Percent Change From Baseline in Total Kidney Volume (TKV) at Week 3
The primary endpoint was percent change from baseline in TKV at Week 3. Total kidney volume is an important measure of disease progression. A 3-week time point is adequate to assess acute effects on kidney cyst shrinkage.
Time frame: Baseline to Week 3
Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS)
The ADPKD-UIS was a self-administered questionnaire designed to measure ADPKD-related urinary symptoms in participants with ADPKD. This instrument contained 11 items in 3 domains (Urinary Frequency, Urinary Urgency, and Nocturia). Each item was scored using a scale of 1 to 5 (a higher score indicated increased difficulty/extremely bothered). The maximum total score is 55; 1: not difficult/not bothered at all; 55: extremely difficult/extremely bothered.
Time frame: Baseline to Week 8
Percent Change From Baseline in TKV at Week 8.
Total kidney volume is an important measure of disease progression. A 3-week time point is adequate to assess acute effects on kidney cyst shrinkage.
Time frame: Baseline to Week 8
The trial was conducted in 177 participants at 41 trial states in the United States.
| Milestone | Tolvaptan Modifed Release (MR) 50 mg | Tolvaptan MR 80 mg | Tolvaptan Immediate Release (IR) 60/30 mg | Placebo |
|---|---|---|---|---|
| Started | 45 | 45 | 44 | 43 |
| Completed | 42 | 40 | 42 | 39 |
| Not completed | 3 | 5 | 2 | 4 |
| Withdrew: Adverse event | 2 | 0 | 1 | 1 |
| Withdrew: Protocol deviation | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 3 | 0 | 2 |
| Withdrew: Participant met withdrawal criteria | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 |
The primary endpoint was percent change from baseline in TKV at Week 3. Total kidney volume is an important measure of disease progression. A 3-week time point is adequate to assess acute effects on kidney cyst shrinkage.
| Percentage change | Tolvaptan MR 50 mg | Tolvaptan MR 80 mg | Tolvaptan IR 60/30 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline in Total Kidney Volume (TKV) at Week 3 | -2.46 ± 4.40 | -2.55 ± 3.85 | -1.17 ± 4.52 | 0.09 ± 5.31 |
The ADPKD-UIS was a self-administered questionnaire designed to measure ADPKD-related urinary symptoms in participants with ADPKD. This instrument contained 11 items in 3 domains (Urinary Frequency, Urinary Urgency, and Nocturia). Each item was scored using a scale of 1 to 5 (a higher score indicated increased difficulty/extremely bothered). The maximum total score is 55; 1: not difficult/not bothered at all; 55: extremely difficult/extremely bothered.
| Unit on a scale | Tolvaptan MR 50 mg | Tolvaptan MR 80 mg | Tolvaptan IR 60/30 mg | Placebo |
|---|---|---|---|---|
| Urinary Frequency | 0.74 ± 0.94 | 0.82 ± 0.83 | 0.99 ± 0.78 | 0.10 ± 0.35 |
| Urinary Urgency | 0.69 ± 0.96 | 0.66 ± 0.77 | 1.01 ± 0.95 | 0.05 ± 0.30 |
| Nocturia | 0.97 ± 1.28 | 1.15 ± 0.89 | 1.36 ± 1.12 | 0.11 ± 0.59 |
Total kidney volume is an important measure of disease progression. A 3-week time point is adequate to assess acute effects on kidney cyst shrinkage.
| Percentage change | Tolvaptan MR 50 mg | Tolvaptan MR 80 mg | Tolvaptan IR 60/30 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline in TKV at Week 8. | -2.04 ± 3.87 | -2.02 ± 3.54 | -0.08 ± 7.31 | 2.13 ± 7.99 |
Collected over Adverse events were collected from the time of signing the informed consent, throughout the 8 week treatment period and for 7 days after the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tolvaptan MR 50 mg | 0/45 (0%) | 3/45 (6.7%) | 27/45 (60%) |
| Tolvaptan MR 80 mg | 0/44 (0%) | 1/44 (2.3%) | 25/44 (56.8%) |
| Tolvaptan IR 60/30 mg | 0/44 (0%) | 1/44 (2.3%) | 32/44 (72.7%) |
| Placebo | 0/42 (0%) | 1/42 (2.4%) | 18/42 (42.9%) |
| Event | Tolvaptan MR 50 mg | Tolvaptan MR 80 mg | Tolvaptan IR 60/30 mg | Placebo |
|---|---|---|---|---|
| Hepatic enzyme increasedInvestigations | 0/45 | 0/44 | 0/44 | 1/42 |
| Alanine aminotransferase increasedInvestigations | 0/45 | 1/44 | 0/44 | 0/42 |
| Liver function test abnormalInvestigations | 0/45 | 0/44 | 1/44 | 0/42 |
| Sinus tachycardiaCardiac disorders | 1/45 | 0/44 | 0/44 | 0/42 |
| Blood creatinine increasedInvestigations | 1/45 | 0/44 | 0/44 | 0/42 |
| DehydrationMetabolism and nutrition disorders | 1/45 | 0/44 | 0/44 | 0/42 |
| Renal painRenal and urinary disorders | 1/45 | 0/44 | 0/44 | 0/42 |
| Event | Tolvaptan MR 50 mg | Tolvaptan MR 80 mg | Tolvaptan IR 60/30 mg | Placebo |
|---|---|---|---|---|
| ThirstGeneral disorders | 15/45 | 15/44 | 19/44 | 6/42 |
| NocturiaRenal and urinary disorders | 14/45 | 14/44 | 18/44 | 3/42 |
| PolyuriaRenal and urinary disorders | 11/45 | 11/44 | 13/44 | 3/42 |
| PollakuriaRenal and urinary disorders | 8/45 | 9/44 | 12/44 | 3/42 |
| Dry mouthGastrointestinal disorders | 7/45 | 7/44 | 2/44 | 1/42 |
| HeadacheNervous system disorders | 1/45 | 1/44 | 7/44 | 1/42 |
| PolydipsiaMetabolism and nutrition disorders | 7/45 | 6/44 | 5/44 | 2/42 |
| FatigueGeneral disorders | 3/45 | 2/44 | 6/44 | 1/42 |
| NauseaGastrointestinal disorders | 2/45 | 1/44 | 2/44 | 4/42 |
| Renal painRenal and urinary disorders | 1/45 | 1/44 | 2/44 | 3/42 |
All participants randomized to treatment.
| Age, Continuous(years) | Tolvaptan MR 50 mg | Tolvaptan MR 80 mg | Tolvaptan IR 60/30 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 34.1 ± 10.1 | 35.8 ± 7.9 | 32.2 ± 7.6 | 33.9 ± 8.1 | 34.0 ± 8.5 |
| Sex: Female, Male(Participants) | Tolvaptan MR 50 mg | Tolvaptan MR 80 mg | Tolvaptan IR 60/30 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 18 | 23 | 20 | 23 | 84 |
| Male | 27 | 22 | 24 | 20 | 93 |
The record gives a start of Oct 2011, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 5 years 1 month after primary completion. A results delay was requested in Jun 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Polycystic Kidney, Autosomal Dominant →
Otsuka Pharmaceutical Development & Commercialization, Inc. →